InvestorsObserver
×
News Home

How Will the Market React to Alnylam Pharmaceuticals, Inc. (ALNY) Stock Getting a Bearish Rating

Thursday, January 28, 2021 02:37 PM | InvestorsObserver Analysts

Mentioned in this article

How Will the Market React to Alnylam Pharmaceuticals, Inc. (ALNY) Stock Getting a Bearish Rating

Alnylam Pharmaceuticals, Inc. (ALNY) stock has fallen 7.49% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.

Sentiment Score - ,bearish
Alnylam Pharmaceuticals, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ALNY!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.

Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.

InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.

Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With ALNY Stock Today?

Alnylam Pharmaceuticals, Inc. (ALNY) stock is lower by -0.73% while the S&P 500 is up 1.75% as of 2:35 PM on Thursday, Jan 28. ALNY has fallen -$1.13 from the previous closing price of $155.39 on volume of 555,882 shares. Over the past year the S&P 500 is higher by 16.49% while ALNY is up 34.47%. ALNY lost -$7.83 per share in the over the last 12 months.

To see the top 5 stocks in the Biotechnology industry click here.

More About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Click Here to get the full Stock Score Report on Alnylam Pharmaceuticals, Inc. (ALNY) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App